Benzinga

Kodiak Sciences announced that its experimental eye drug performs on par with Regeneron's established eye medicine, positioning the biotech as a potential competitor in the treatment of retinal diseases. The claim, reported by Benzinga, puts a spotlight on Kodiak's clinical data and its ability to challenge Regeneron's dominance in the ophthalmology market, where its blockbuster therapy has long set the standard of care.